Inter- and intraclade neutralization of human immunodeficiency virus type 1: genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes.
about
Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines.Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodiesClade, Country and Region-specific HIV-1 Vaccines: Are they necessary?Maternal plasma viral load and neutralizing/enhancing antibodies in vertical transmission of HIV: a non-randomized prospective studyThe Antibody Response against HIV-1Generation of neutralizing antibodies and divergence of SIVmac239 in cynomolgus macaques following short-term early antiretroviral therapyAdditive Effects Characterize the Interaction of Antibodies Involved in Neutralization of the Primary Dualtropic Human Immunodeficiency Virus Type 1 Isolate 89.6Preclinical and clinical development of a multi-envelope, DNA-virus-protein (D-V-P) HIV-1 vaccineInternational network for comparison of HIV neutralization assays: the NeutNet report IIA comprehensive panel of near-full-length clones and reference sequences for non-subtype B isolates of human immunodeficiency virus type 1.Antibody elicited against the gp41 N-heptad repeat (NHR) coiled-coil can neutralize HIV-1 with modest potency but non-neutralizing antibodies also bind to NHR mimetics.Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41.A novel human antibody against human immunodeficiency virus type 1 gp120 is V1, V2, and V3 loop dependent and helps delimit the epitope of the broadly neutralizing antibody immunoglobulin G1 b12.An affinity-enhanced neutralizing antibody against the membrane-proximal external region of human immunodeficiency virus type 1 gp41 recognizes an epitope between those of 2F5 and 4E10International network for comparison of HIV neutralization assays: the NeutNet report.A human immunodeficiency virus prime-boost immunization regimen in humans induces antibodies that show interclade cross-reactivity and neutralize several X4-, R5-, and dualtropic clade B and C primary isolatesBreadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variablesHIV neutralizing antibodies: clinical correlates and implications for vaccines.Biologic and genetic characterization of a panel of 60 human immunodeficiency virus type 1 isolates, representing clades A, B, C, D, CRF01_AE, and CRF02_AG, for the development and assessment of candidate vaccines.Genetic subtype-independent inhibition of human immunodeficiency virus type 1 replication by CC and CXC chemokines.Extent of antigenic diversity in the V3 region of the surface glycoprotein, gp120, of human immunodeficiency virus type 1 group M and consequences for serotypingEvidence that antibody-mediated neutralization of human immunodeficiency virus type 1 by sera from infected individuals is independent of coreceptor usageNeutralizing antibodies in sera from macaques infected with chimeric simian-human immunodeficiency virus containing the envelope glycoproteins of either a laboratory-adapted variant or a primary isolate of human immunodeficiency virus type 1.An envelope modification that renders a primary, neutralization-resistant clade B human immunodeficiency virus type 1 isolate highly susceptible to neutralization by sera from other clades.Mapping of epitopes exposed on intact human immunodeficiency virus type 1 (HIV-1) virions: a new strategy for studying the immunologic relatedness of HIV-1.Study of the V3 loop as a target epitope for antibodies involved in the neutralization of primary isolates versus T-cell-line-adapted strains of human immunodeficiency virus type 1Antibody neutralization-resistant primary isolates of human immunodeficiency virus type 1.Heterologous epitope-scaffold prime:boosting immuno-focuses B cell responses to the HIV-1 gp41 2F5 neutralization determinant.Search for the mechanism of genetic variation in the pro gene of human immunodeficiency virus.Minimal incidence of serum antibodies reactive with intact primary isolate virions in human immunodeficiency virus type 1-infected individualsGenetic subtypes, humoral immunity, and human immunodeficiency virus type 1 vaccine development.Immunoglobulin G (IgG) and IgA, but also nonantibody factors, account for in vitro neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by serum and plasma of HIV-infected patients.Evaluating the immunogenicity of a disulfide-stabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1Epitope specificities of broadly neutralizing plasmas from HIV-1 infected subjectsMolecular typing of enteroviruses: current status and future requirements. The European Union Concerted Action on Virus Meningitis and EncephalitisMagnitude and breadth of a nonprotective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccineSuperinfection by discordant subtypes of HIV-1 does not enhance the neutralizing antibody response against autologous virus.Regional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus type 1 from South Africa.The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120.Serum neutralizing activities from a Beijing homosexual male cohort infected with different subtypes of HIV-1 in China.
P2860
Q24531479-0890419E-D9B4-433A-B9DB-08B8DD0BE64CQ24561905-8F8061A4-EE03-4F4D-A5AF-92F274C5CEF5Q24803275-CC3AEF1A-71EE-419E-94DC-8E2118E77149Q24804378-53075452-DAFC-4D18-B0A9-D6A4F295A2DDQ27000889-4941F416-ABFB-4880-9CDF-7B4836B6FD28Q27313556-84C8BE1E-7757-4452-802C-E3D18CDA4475Q27469855-B1EC61AF-A02D-4075-B662-C09B03306E8AQ28387636-A06CBE41-D22C-490D-BAAF-4F9B585090D3Q28730045-22A491D3-A29A-48C0-A474-327628BE2E9FQ30430708-4E358486-8760-4B32-AE31-790CD38962B4Q30843874-6162CF8B-4D04-4338-88D1-3E074808DFFAQ31016954-52E1F277-4162-4172-A988-F51A1D888F29Q31143293-6540B421-7EF3-4A49-A094-5EE6304335B4Q33272711-3FDA70F5-5D87-46B7-AF24-99E51987AAFDQ33410826-F44FF647-F5E4-44CD-89D5-1D4DE8AD6EAFQ33603494-0958FA76-363F-49BC-9D02-23AC62BD266FQ33614495-4C77588A-19F8-4CF0-AC5B-40621744EE13Q33703451-9EF47734-2F91-4D5B-859D-AFB760BDB987Q33780524-9DB704A4-904E-4269-9B18-91EFE9710D72Q33782007-7674A70F-BDB6-407C-A31C-DB4BD96BD2C6Q33782134-17D3B6AE-0B4D-48F8-A8BA-35E688A68D60Q33782296-54408EFC-DFFF-47BE-A050-00AE60EB271CQ33783516-486CB8A8-1918-4148-A3A0-1A35E789BA51Q33784679-21AC752D-0B17-40F8-8A63-F3427FC0E784Q33785510-2D22F717-F341-4C93-86B0-2DEDFE65E6A8Q33786049-4BAB271E-BA7B-41CD-8988-358BF50089B7Q33786382-3C81A1BE-A5DF-44FB-A935-195ABD6BA71EQ33812812-8AA3BCE3-D5B0-436D-9B26-D15F7BBAACF5Q33819390-F23ABA6A-F3A5-4B97-9587-5F6A524D5D9BQ33823853-56A7313E-8C47-4C4C-B4A5-142BD485B62DQ33842152-8C072F40-8D00-4E0C-A0E0-A0260BB19F04Q33852361-B4D76897-101E-4574-BC7D-6529A86103F9Q33883887-8F4BF00C-A7C2-43B2-B46B-4C924130D6C6Q33888559-D4D00A75-6D69-4743-AA52-86F19DD694B0Q33992691-44B809AD-BEA2-400C-B5AD-BB5698F42FDCQ34157802-B4D81771-CC1C-43D8-B110-BE6D6670FE9EQ34312037-35DE22BC-41D9-40E2-884F-F4E3D3762064Q34332009-A0DD7E2A-D0BD-40AD-BC7C-96E56BBE5BA2Q34342352-5521CA8E-F067-4329-952D-ADC93D35D1A5Q34456367-36459D45-CBDF-4C56-BA5C-F68598A104EC
P2860
Inter- and intraclade neutralization of human immunodeficiency virus type 1: genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
Inter- and intraclade neutrali ...... to gp120 antigenic serotypes.
@ast
Inter- and intraclade neutrali ...... to gp120 antigenic serotypes.
@en
type
label
Inter- and intraclade neutrali ...... to gp120 antigenic serotypes.
@ast
Inter- and intraclade neutrali ...... to gp120 antigenic serotypes.
@en
prefLabel
Inter- and intraclade neutrali ...... to gp120 antigenic serotypes.
@ast
Inter- and intraclade neutrali ...... to gp120 antigenic serotypes.
@en
P2093
P2860
P1433
P1476
Inter- and intraclade neutrali ...... d to gp120 antigenic serotypes
@en
P2093
P2860
P304
P407
P577
1996-01-01T00:00:00Z